Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.64 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395181 | 0.78 | ALOX5 (1.00) | ALOX5GPR35HSD17B10 | |
| SCHEMBL10460612 | 0.74 | CA12 (0.45) | GPR35USP2POLBHPGDALOX15 | |
| SCHEMBL22024967 | 0.73 | GPR35 (0.45) | GPR35USP2POLBHPGDALOX15 | |
| SCHEMBL10480444 | 0.73 | ALOX5 (0.54) | ALOX5ALOX15ALOX12 | |
| SCHEMBL6341962 | 0.70 | ALOX5 (0.68) | ALOX5ALOX15ALOX12 | |
| SCHEMBL10480428 | 0.70 | ALOX5 (0.64) | ALOX5 | |
| SCHEMBL2397463 | 0.69 | KMT2A (0.58) | ALOX5USP2HSD17B10CA12CA1 | |
| SCHEMBL10480284 | 0.67 | ALOX5 (0.71) | ALOX5 | |
| SCHEMBL11684319 | 0.66 | GPR35 (0.53) | GPR35USP2POLBHPGDALOX15 | |
| SCHEMBL22561687 | 0.65 | MAPT (0.40) | ALOX5GPR35USP2POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC. | 2005-04-28 | — | — | US | disclosed |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-24 | — | — | US | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885GPR35 995/4885USP2 1661/4885 |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885GPR35 1103/4885USP2 1564/4885 |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885GPR35 995/4885USP2 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.